Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oncology/Oropharyngeal Cancer

Oropharyngeal Cancer

40

Pipeline Programs↗

51

Active Trials↗

23

Companies Involved↗

Oropharyngeal Cancer is a moderately active landscape with 40 programs across 23 companies. 8 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

63/100

Pipeline Velocity

34/100

Mech. Concentration

15/100

Completion Rate

63/100

Attrition Rate

10/100

Pipeline

Programs by Phase

Preclinical10

Bintrafusp Alfa

EMD Serono Research & Development Institute, Inc.

PDS01ADC

National Cancer Institute (NCI)

Entinostat

Syndax Pharmaceuticals

Photodynamic Therapy

Roswell Park Cancer Institute

Temoporfin

University of Arkansas

Phase 16

NEXI-003 T Cells

NexImmune Inc.

Flubhpve6e7

BlueSky Immunotherapies GmbH

Cyclophosphamide

Baxter Healthcare Corporation

Fludarabine

Sanofi

Elimusertib

Bayer

Phase 216

Albumin-Bound Paclitaxel

Bristol-Myers Squibb

HPV16 Ct-DNA Dosing

UNICANCER

Balstilimab

Agenus Inc.

Two IM Injections Lenti-HPV-07

Theravectys S.A.

One IM Injection Lenti-HPV-07

Theravectys S.A.

Phase 38

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Carboplatin

Avyxa

Paclitaxel

Teva

Cisplatin Based Chemotherpay

Tata Memorial Centre

Durvalumab

AstraZeneca

Approved

No programs

Analysis

Modality Breakdown

71%

Small molecule

24 of 34 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 34 classified programs, each share of the total. Modality classified for 98% of 40 pipeline programs.

Analysis

Trial Status

71

clinical trials

Recruiting26 · 37%

Active, not recruiting17 · 24%

Completed12 · 17%

Not yet recruiting8 · 11%

Terminated4 · 6%

Withdrawn3 · 4%

Other1 · 1%

Clinical Trials

Trial Activity

71 trials

Multidimensional and Multimodal Profiling of Oropharyngeal Carcinoma

Recruiting·SStanford University·N/A·NCT05880797·1,000 enrolled

Phase 1/1b Study of AKT Inhibitor Ipatasertib With Chemoradiation for Locally Advanced Head and Neck Cancer

Recruiting·National Cancer Institute (NCI)·Phase 1·NCT05172245·46 enrolled

A Phase II Randomized Trial of Neoadjuvant Chemotherapy or Chemo-Immunotherapy in Patients With Recurrent/Persistent PD-L1 Enriched Squamous Cell Carcinoma of the Head and Neck Undergoing Salvage Surgery (NEOPOLIS)

Recruiting·National Cancer Institute (NCI)·Phase 2·NCT07195734·180 enrolled

Phase I Trial of ATR Inhibitor Camonsertib Combined With Stereotactic Body Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma

Recruiting·National Cancer Institute (NCI)·Phase 1·NCT07156227·39 enrolled

A Phase 1/2, Open-label Trial to Evaluate Safety, Immunogenicity, and Anti-tumor Activity of VB10.16 in Combination With Pembrolizumab in Patients With Unresectable Recurrent or Metastatic HPV16-positive Head and Neck Squamous Cell Carcinoma

Recruiting·NNykode Therapeutics ASA·Preclinical·NCT06016920·110 enrolled

A Randomized, Masked, Placebo Controlled, Phase II Trial Of Concurrent Chemoradiation With BMX-001 In Patients With Head And Neck Squamous Cell Carcinoma Receiving Concurrent Chemoradiation

Recruiting·NRG Oncology·Phase 2·NCT06532279·98 enrolled

Radiotherapy With Concurrent Cetuximab vs. Carboplatin and Paclitaxel in Patients With Stage III-IVB Head and Neck Cancer With a Contraindication to Cisplatin: A Pragmatic Phase III Randomized Trial

Recruiting·NRG Oncology·Phase 3·NCT07441681·454 enrolled

Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study

Recruiting·JJonathan Schoenfeld, MD, MPH·Phase 2·NCT04900623·145 enrolled

ULTRA-HPV Using Circulating Tumor DNA to Risk Adapt Post-operative Therapy for HPV Associated Oropharyngeal Cancer

Recruiting·—·Phase 2·NCT06445114·50 enrolled

The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial)

Recruiting·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT05419089·83 enrolled

Validation of a New Method for Monitoring HPV Infection in Patients With Head and Neck Cancers

Recruiting·MMasaryk Memorial Cancer Institute·Preclinical·NCT07718620·35 enrolled

Non-Randomized Phase 2 Trial of Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma

Recruiting·WWashington University School of Medicine·Phase 2·NCT04852328·30 enrolled

Ototoxicity Monitoring and Remote Audiometry

Recruiting·EEmory University·Preclinical·NCT06662058·118 enrolled

An Open-Label Phase II Clinical Trial Assessing the Safety, Feasibility, Efficacy and Immunological Correlates of Heterologous Prime-Boost With pBI-11 (IM) and TA-HPV (IM) Combined With Pembrolizumab as Treatment for Patients With Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer

Recruiting·—·Phase 2·NCT05799144·54 enrolled

SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer. A Phase III Randomized Controlled Trial

Recruiting·CCanadian Cancer Trials Group·Phase 3·NCT05451004·510 enrolled

Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)